Uri Galili

Q: What Schools Are Affiliated With Uri Galili

Uri Galili is affiliated with the following schools: University of California, Berkeley, Stanford University, University of Massachusetts Medical School, Rush University

Uri Galili's AcademicInfluence.com Rankings

Uri Galili

Computer Science

#5582

World Rank

#5896

Historical Rank

Machine Learning

#1538

World Rank

#1560

Historical Rank

Artificial Intelligence

#1770

World Rank

#1802

Historical Rank

Database

#2728

World Rank

#2852

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Uri Galili's Degrees

PhD Computer Science Stanford University
Masters Computer Science Stanford University
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Uri Galili Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Uri Galili's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. (1988) (876)
A unique natural human IgG antibody with anti-alpha-galactosyl specificity (1984) (653)
Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. (1993) (627)
Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora (1988) (501)
Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1----3Gal epitope in primates. (1987) (495)
Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1----3)-linked galactose residues (1985) (381)
The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: A carbohydrate of unique evolution and clinical relevance (2008) (320)
Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. (1991) (300)
On the Role of Cell Surface Carbohydrates and their Binding Proteins (lectins) in Tumor Metastasis (2004) (278)
The α‐gal epitope and the anti‐Gal antibody in xenotransplantation and in cancer immunotherapy (2005) (272)
One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. (1993) (222)
The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies (1987) (211)
The α-Gal epitope (Galα1-3Galβ1-4GlcNAc-R) in xenotransplantation. (2001) (187)
Anti‐Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits (2013) (174)
The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. (2005) (169)
The formation of stable E rosettes after neuraminidase treatment of either human peripheral blood lymphocytes or of sheep red blood cells. (1974) (159)
Immunogenic Gal alpha 1----3Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. (1989) (155)
Differential immune responses to alpha-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. (2000) (152)
Reversal of diabetes in non‐immunosuppressed rhesus macaques by intraportal porcine islet xenografts precedes acute cellular rejection (2004) (134)
The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. (2008) (128)
Porcine and bovine cartilage transplants in cynomolgus monkey: II. Changes in anti-Gal response during chronic rejection. (1997) (125)
A sensitive assay for measuring alpha-Gal epitope expression on cells by a monoclonal anti-Gal antibody. (1998) (125)
Porcine cartilage transplants in the cynomolgus monkey. III. Transplantation of alpha-galactosidase-treated porcine cartilage. (1998) (121)
Evolution and pathophysiology of the human natural anti-α-galactosyl IgG (anti-Gal) antibody (2004) (116)
Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces. (1992) (115)
Distribution of Gal.alpha.1.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc residues on secreted mammalian glycoproteins (thyroglobulin, fibrinogen, and immunoglobulin G) as measured by a sensitive solid-phase radioimmunoassay (1990) (112)
Molecular mimicry in the recognition of glycosphingolipids by Galα3Galβ4GlcNAcβ-binding Clostridium difficile toxin A, human natural anti α-galactosyl IgG and the monoclonal antibody Gal-13: characterization of a binding-active human glycosphingolipid, non-identical with the animal receptor (1996) (109)
Replacement of Human Anterior Cruciate Ligaments with Pig Ligaments: A Model for Anti-Non-Gal Antibody Response in Long-Term Xenotransplantation (2007) (104)
Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase. (1999) (103)
Lectin-induced apoptosis of tumour cells. (1993) (103)
Defining the minimal size of catalytically active primate alpha 1,3 galactosyltransferase: structure-function studies on the recombinant truncated enzyme. (1994) (101)
Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: type II activation. (1998) (96)
Porcine and bovine cartilage transplants in cynomolgus monkey: I. A model for chronic xenograft rejection. (1997) (93)
The effect of radiation therapy on lymphocyte subpopulations in cancer patients (1976) (93)
Immunogenicity of Influenza Virus Vaccine Is Increased by Anti-Gal-Mediated Targeting to Antigen-Presenting Cells (2007) (92)
Adult and neonatal anti‐Gal response in knock‐out mice for α1,3galactosyltransferase (1998) (90)
Changes in cell surface glycosylation in alpha1,3-galactosyltransferase knockout and alpha1,2-fucosyltransferase transgenic mice. (1997) (86)
Identification of erythrocyte Gal alpha 1-3Gal glycosphingolipids with a mouse monoclonal antibody, Gal-13. (1987) (85)
Immune response, accommodation, and tolerance to transplantation carbohydrate antigens. (2004) (84)
The natural anti‐α‐galactosyl IgG on human normal senescent red blood cells (1986) (84)
Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. (1997) (82)
Anti-alpha-galactosyl immunoglobulin A (IgA), IgG, and IgM in human secretions (1995) (80)
Demonstration of a natural antigalactosyl IgG antibody on thalassemic red blood cells. (1983) (80)
Increased Immunogenicity of Human Immunodeficiency Virus gp120 Engineered To Express Galα1-3Galβ1-4GlcNAc-R Epitopes (2006) (78)
Excessive binding of natural anti-alpha-galactosyl immunoglobin G to sickle erythrocytes may contribute to extravascular cell destruction. (1986) (77)
Intratumoral Injection of α-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines (2007) (71)
Anterior cruciate ligament reconstruction with a porcine xenograft: a serologic, histologic, and biomechanical study in primates. (2007) (70)
Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody. (2009) (70)
Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by alpha 1,3 galactosyltransferase gene transfection. (1995) (68)
Rapid Recruitment and Activation of Macrophages by Anti-Gal/α-Gal Liposome Interaction Accelerates Wound Healing (2011) (66)
Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody. (1993) (66)
Differential expression of alpha-GAL epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on pig and mouse organs. (2000) (63)
Human anti-Gal heavy chain genes. Preferential use of VH3 and the presence of somatic mutations. (1995) (60)
Inhibition of anti-Gal IgG binding to porcine endothelial cells by synthetic oligosaccharides. (1996) (59)
Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody. (1996) (59)
Increased anti-Gal activity in diabetic patients transplanted with porcine islet cells. (1996) (59)
Xenotransplantation and ABO incompatible transplantation: the similarities they share. (2006) (56)
ABNORMAL EXPRESSION OF α-GALACTOSYL EPITOPES IN MAN A Trigger for Autoimmune Processes? (1989) (55)
Differential host-dependent expression of alpha-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model. (1994) (55)
The formation of stable E-rosettes by human T lymphocytes activated in mixed lymphocyte reactions. (1976) (51)
Activated T cells in the synovial fluid of arthritic patients: characterization and comparison with in vitro activated human and murine T cells in cooperation with monocytes in cytotoxicity. (1979) (51)
Discovery of the natural anti‐Gal antibody and its past and future relevance to medicine (2013) (50)
Evolution in primates by "Catastrophic-selection" interplay between enveloped virus epidemics, mutated genes of enzymes synthesizing carbohydrate antigens, and natural anti-carbohydrate antibodies. (2019) (50)
Accelerated healing of skin burns by anti-Gal/alpha-gal liposomes interaction. (2010) (49)
Separation and characteristics of tumor-infiltrating lymphocytes in man. (1980) (49)
Synthesis of α-Galactosyl Epitopes by Recombinant α1,3Galactosyltransferase for Opsonization of Human Tumor Cell Vaccines by Anti-Galactose (1996) (48)
Erythrocyte membrane alterations in beta-thalassaemia. (1985) (48)
Antibody-mediated accommodation of heart grafts expressing an incompatible carbohydrate antigen (2003) (48)
Subpopulations of human thymus cells differing in their capacity to form stable E-rosettes and in their immunologic reactivity. (1975) (47)
Significance of the Evolutionary α1,3-Galactosyltransferase (GGTA1) Gene Inactivation in Preventing Extinction of Apes and Old World Monkeys (2014) (46)
Suppression of α-galactosyl epitopes synthesis and production of the natural anti-Gal antibody: a major evolutionary event in ancestral Old World primates (1995) (45)
Natural species-restricted attachment of human and murine T lymphocytes to various cells. (1978) (45)
Metabolic and ultrastructural aspects of the in vitro lysis of chronic lymphocytic leukemia cells by glucocorticoids. (1982) (44)
Age-associated changes in subpopulations of human lymphocytes. (1977) (43)
α1,3Galactosyltransferase knockout pigs produce the natural anti‐Gal antibody and simulate the evolutionary appearance of this antibody in primates (2013) (42)
The natural anti-Gal antibody, the B-like antigen, and human red cell aging. (1988) (42)
Variations in activity of the human natural anti-Gal antibody in young and elderly populations. (1995) (42)
Induced Anti-Non Gal Antibodies in Human Xenograft Recipients (2012) (42)
The natural anti-Gal antibody. (1999) (39)
Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes. (2010) (37)
Interaction of Baboon Anti-α-Galactosyl Antibody with Pig Tissues (1999) (36)
Human T lymphocytes become glucocorticoid-sensitive upon immune activation. (1980) (36)
Autologous tumor vaccines processed to express α-gal epitopes: a practical approach to immunotherapy in cancer (2004) (34)
Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells. (2005) (34)
Reduction of metastatic properties of BL6 melanoma cells expressing terminal fucose(alpha)1-2-galactose after alpha1,2-fucosyltransferase cDNA transfection. (1997) (33)
Intratumoral injection of α-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity (2009) (33)
Elimination of anti-Gal B cells by alpha-Gal ricin1. (2002) (33)
Anti-gal A/B, a novel anti-blood group antibody identified in recipients of abo-incompatible kidney allografts1 (2002) (33)
Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: type I activation. (1998) (33)
Genes coding evolutionary novel anti-carbohydrate antibodies: studies on anti-Gal production in alpha 1,3galactosyltransferase knock out mice. (2000) (32)
Accelerated Porcine Wound Healing after Treatment with &agr;-Gal Nanoparticles (2012) (32)
Activated T lymphocytes in infiltrates and draining lymph nodes of nasopharyngeal carcinoma (1980) (32)
Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes. (2006) (32)
Comparison of serum anti-band 3 and anti-Gal antibody binding to density-separated human red blood cells. (1991) (31)
Molecular mimicry in the recognition of glycosphingolipids by Gal alpha 3 Gal beta 4 GlcNAc beta-binding Clostridium difficile toxin A, human natural anti alpha-galactosyl IgG and the monoclonal antibody Gal-13: characterization of a binding-active human glycosphingolipid, non-identical with the ani (1996) (31)
Tolerance induction to a mammalian blood group-like carbohydrate antigen by syngeneic lymphocytes expressing the antigen, II: tolerance induction on memory B cells. (2003) (31)
Mouse-heart grafts expressing an incompatible carbohydrate antigen. II. Transition from accommodation to tolerance (2004) (30)
Distribution of Gal alpha 1----3Gal beta 1----4GlcNAc residues on secreted mammalian glycoproteins (thyroglobulin, fibrinogen, and immunoglobulin G) as measured by a sensitive solid-phase radioimmunoassay. (1990) (30)
Activated T cells in the synovial fluid of arthritic patients. II. In vitro activation of the autologous blood lymphocytes. (1981) (29)
High‐affinity anti‐Gal immunoglobulin G in chronic rejection of xenografts (1997) (29)
Synthesis of α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) on human tumor cells by recombinant α1,3galactosyltransferase produced in Pichia pastoris (2001) (28)
Exposure to phorbol diester (TPA) in vitro as an aid in the classification of blasts in human myelogenous and lymphoid leukemias: In vitro differentiation, growth patterns, and ultrastructural observations (1982) (28)
In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the α1,3galactosyltransferase gene (2005) (28)
Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes (2020) (27)
Human prothymocytes. Membrane properties, differentiation patterns, glucocorticoid sensitivity, and ultrastructural features (1980) (27)
Synthesis of α-gal epitopes on influenza virus vaccines, by recombinant α1,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody (1997) (27)
Natural anti-carbohydrate antibodies contributing to evolutionary survival of primates in viral epidemics? (2016) (27)
Evolution of α1,3Galactosyltransferase and of the α-Gal Epitope (1999) (26)
Glucocorticoid induced cytolysis of human normal and malignant lymphocytes. (1983) (26)
Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer (2015) (26)
Contribution of anti-Gal to primate and human IgG binding to porcine endothelial cells. (1995) (25)
Triple immunosuppression reduces mononuclear cell infiltration and prolongs graft life in pig-to-newborn baboon cardiac xenotransplantation. (1998) (25)
A human antibody binds to alpha-galactose receptors and mimics the effects of Clostridium difficile toxin A in rat colon. (1996) (25)
Direct killing of xenograft cells by CD8+ T cells of discordant xenograft recipients1 (2002) (23)
Specific stimulation of Graves' disease thyrocytes by the natural anti-Gal antibody from normal and autologous serum. (1994) (23)
EA Rosette Formation: a Simple Means to Increase Sensitivity of the Antiglobulin Test in Patients with Anti Red Cell Antibodies (1981) (23)
Avoiding detrimental human immune response against Mammalian extracellular matrix implants. (2015) (23)
Profiling terminal N-acetyllactosamines of glycans on mammalian cells by an immuno-enzymatic assay (2006) (23)
Human Natural Antibodies to Mammalian Carbohydrate Antigens as Unsung Heroes Protecting against Past, Present, and Future Viral Infections (2020) (23)
Cancer immunotherapy by intratumoral injection of α-gal glycolipids. (2012) (23)
Expression of alpha-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine. (2003) (23)
Control of metastatic properties of BL6 melanoma cells by H-2Kb gene: immunological and nonimmunological mechanisms (1993) (22)
Lymphocyte subpopulations in chronic active hepatitis: increase in lymphocytes forming stable E-rosettes. (1975) (22)
Understanding the Induced Antibody Response (2001) (22)
The in vitro sensitivity of leukemic and normal leukocytes to hydrocortisone induced cytolysis. (1980) (22)
Significance of anti-Gal IgG in chronic xenograft rejection. (1999) (22)
The natural anti-Gal antibody: evolution and autoimmunity in man. (1991) (21)
Analysis of the peanut agglutinin-binding site as a differentiation marker of normal and malignant human lymphoid cells. (1981) (21)
Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. (1996) (21)
Expression of α-gal epitopes on HeLa cells transduced with adenovirus containing α1,3galactosyltransferase cDNA (2002) (21)
Tolerance induction to a mammalian blood group-like carbohydrate antigen by syngeneic lymphocytes expressing the antigen. (2003) (21)
Xenogeneic thyroid-stimulating hormone-like activity of the human natural anti-Gal antibody. Interaction of anti-Gal with porcine thyrocytes and with recombinant human thyroid-stimulating hormone receptors expressed on mouse cells. (1993) (20)
Evolution of alpha 1,3galactosyltransferase and of the alpha-Gal epitope. (1999) (20)
Anti-αgalactosyl (Anti-Gal) Antibody Damage Beyond Hyperacute Rejection (1997) (20)
α-Galactosyl (Galα1-3Galβ1-4GlcNAc-R) epitopes on human cells: synthesis of the epitope on human red cells by recombinant primate α1,3galactosyltransferase expressed in E.coli (1995) (18)
Topical α‐gal nanoparticles accelerate diabetic wound healing (2020) (17)
Cloning of anti-Gal Fabs from combinatorial phage display libraries: structural analysis and comparison of Fab expression in pComb3H and pComb8 phage. (1997) (17)
Use of the enzyme-linked immunoadsorbent assay to monitor the purification of glycosphingolipid antigens by high-performance liquid chromatography. (1987) (17)
alpha-galactosyl epitopes on glycoproteins of porcine renal extracellular matrix. (2000) (16)
Acceleration of Wound Healing by α-gal Nanoparticles Interacting with the Natural Anti-Gal Antibody (2015) (16)
a-GALACTOSYL EPITOPE-MEDIATED ACTIVATION OF PORCINE AORTIC ENDOTHELIAL CELLS (1998) (15)
Human anti-Gal heavy chain genes (1995) (14)
Interaction between anti-Gal and human tumor cells: a natural defense mechanism? (1989) (14)
Human T lymphocyte receptors for sheep red blood cells and specific antigens: are they identical sites on the cell membrane? (1977) (14)
α-Gal Nanoparticles in Wound and Burn Healing Acceleration. (2017) (14)
Induction of immune tolerance to a transplantation carbohydrate antigen by gene therapy with autologous lymphocytes transduced with adenovirus containing the corresponding glycosyltransferase gene (2004) (13)
Effects of dexamethasone on proliferation of autologous fibroblasts and on the immune profile in women undergoing pelvic surgery for infertility. (1983) (13)
Loss of net negative surface charge during MLC stimulation of human T lymphocytes: correlation to "stable" E-rosette formation and natural attachment to normal and malignant target cells. (1979) (12)
Preparation of Autologous Leukemia and Lymphoma Vaccines Expressing α-Gal Epitopes (2001) (12)
A naturally occurring anti-alpha-galactosyl IgG recognizing senescent human red cells. (1985) (12)
Abnormal expression of alpha-galactosyl epitopes in man. A trigger for autoimmune processes? (1989) (12)
In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of α-gal Glycolipids (2010) (12)
Conversion of Tumors into Autologous Vaccines by Intratumoral Injection of α-Gal Glycolipids that Induce Anti-Gal/α-Gal Epitope Interaction (2011) (12)
α-Gal and Anti-Gal (1999) (12)
Lymphocytes of Hodgkin's biopsies exhibit: stable E-rosette formation, natural attachment and glucocorticoid sensitivity, similar to immunoactivated T cells. (1980) (11)
The natural anti-alpha-galactosyl IgG on human normal senescent red blood cells. (1986) (11)
Activated T lymphocytes within human solid tumors (1979) (11)
Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma (2016) (10)
Cellular Dehydration and Immunoglobulin Binding in Senescent Neonatal Erythrocytes (1988) (10)
Be13, a human T-leukemia cell line highly sensitive to dexamethasone-induced cytolysis. (1984) (10)
Synthesis of alpha-gal epitopes on influenza virus vaccines, by recombinant alpha 1,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody. (1997) (10)
Association between HLA determinants and complement receptors on human lymphocytes. (2008) (10)
Host Synthesized Carbohydrate Antigens on Viral Glycoproteins as “Achilles’ Heel” of Viruses Contributing to Anti-Viral Immune Protection (2020) (10)
Synthesis of alpha-gal epitopes (Galalpha1-3Galbeta1-4GlcNAc-R) on human tumor cells by recombinant alpha1,3galactosyltransferase produced in Pichia pastoris. (2001) (10)
Significance of α-Gal (Galα1-3Galβ1-4GlcNAc-R) Epitopes and α1, 3 Galactosyltransferase in Xenotransplantation (1999) (10)
The two antibody specificities within human anti-blood group B antibodies. (1988) (10)
Evidence that tilapia islets do not express α‐(1,3)gal: implications for islet xenotransplantation (2004) (9)
Biosynthesis of α-Gal Epitopes (Galα1-3Galβ1-4GlcNAc-R) and Their Unique Potential in Future α-Gal Therapies (2021) (9)
Differential expression of α-Gal epitopes on pig and mouse organs (2000) (9)
Antigenic differences between T and B lymphocytes in man. (1974) (9)
Determination of ABO Blood Group Zygosity by an Antiglobulin Rosetting Technique and Cell‐Based Enzyme Immunoassay (1986) (9)
Anti-Gal in Humans and Its Antigen the α-Gal Epitope (2018) (8)
Studies on the formation of E-rosettes by human T lymphocytes and thymus cells. Effects of temperature, metabolic inhibitors and anti-T sera. (1975) (8)
Identification of b cells with receptors for α-Gal epitopes (Galα 1-3Galβ1-4GlcNac-R) in xenograft recipients (2000) (7)
Blood lymphocytes in infectious mononucleosis share the following characteristics with activated T cells: natural attachment, stable E rosetting and glucocorticoid sensitivity. (1980) (7)
The natural anti-alpha-galactosyl IgG in seminal fluid. A simple means to determine damage to the blood-genital tract barrier in infertile males. (1992) (7)
New World monkeys as a primate model for xenografts in the absence of anti-Gal. (1996) (7)
*Induced Remodeling of Porcine Tendons to Human Anterior Cruciate Ligaments by α-GAL Epitope Removal and Partial Cross-Linking (2017) (7)
Enhancement of autologous tumor vaccine immunogenicity by anti-Gal. (1999) (7)
Interaction of baboon anti-alpha-galactosyl antibody with pig tissues. (1999) (7)
Macrophages Recruitment and Activation by α-gal NanoparticlesAccelerate Regeneration and Can Improve Biomaterials Efficacy in TissueEngineering (2013) (7)
Preparation of autologous leukemia and lymphoma vaccines expressing alpha-gal epitopes. (2001) (7)
Graves' disease as a model for anti-Gal involvement in autoimmune diseases. (1999) (7)
Antigen-Mediated, Macrophage-Stimulated, Accelerated Wound Healing Using &agr;-Gal Nanoparticles (2018) (7)
Differential immune response to carbohydrate epitopes on allo- and xenografts: implications for accommodation. (2000) (6)
Prothymocytes in postirradiation regenerating rat thymuses: a model for studying early stages in T cell differentiation. (1983) (6)
Conversion of tumors into autologous vaccines by intratumoral injection of alpha-Gal glycolipids that induce anti-Gal/alpha-Gal epitope interaction (2014) (6)
Intracellular protease activity in glucocorticoid-mediated thymolysis. (1982) (6)
α-gal and anti-gal : α1,3-galactosyltransferase, α-gal epitopes, and the natural anti-gal antibody subcellular biochemistry (1999) (6)
alpha-Gal epitopes on viral glycoproteins. (1999) (6)
Evolution of the Galα1-3Galβ1-4GlcNAc-R Epitope in Mammals (1990) (6)
α-Galactosyl antibody redistributes α-galactosyl at the surface of pig blood and endothelial cells (1999) (6)
Human Anti-Gal and Anti-Non-Gal Immune Response to Porcine Tissue Implants (2015) (6)
α-Gal Epitopes on Viral Glycoproteins (1999) (6)
XX/XY lymphoid chimerism in a boy with fatal lymphohistiocytic proliferation. (1981) (5)
Preventing anti-Gal response in xenograft recipients by an α-gal toxin (2001) (5)
Anti-Gal and human red cell aging. (1989) (5)
The nature of elicited xenoantibodies. (2001) (5)
The α-Galactosyl Epitope (Galα1-3Ga1β1-4GIcNAc-R) and the Natural Anti-Gal Antibody (1997) (5)
Expression of alpha-gal epitopes on HeLa cells transduced with adenovirus containing alpha1,3galactosyltransferase cDNA. (2002) (5)
The alpha-galactosyl epitope on human normal and autoimmune thyroid cells. (1991) (5)
In situ conversion of tumors into autologous tumor-associated antigen vaccines by intratumoral injection of α-gal glycolipids (2013) (5)
Near Complete Repair After Myocardial Infarction in Adult Mice by Altering the Inflammatory Response With Intramyocardial Injection of α-Gal Nanoparticles (2021) (5)
Alpha-Galactosyl (Anti-Gal) Autoantibodies (1996) (4)
Evidence that tilapia islets do not express alpha-(1,3)gal: implications for islet xenotransplantation. (2004) (4)
In Situ “Humanization” of Porcine Bioprostheses: Demonstration of Tendon Bioprostheses Conversion into Human ACL and Possible Implications for Heart Valve Bioprostheses (2021) (4)
Glucocorticoid-induced lysis of human leukemia cells. (1988) (4)
The Rosetting Antiglobulin Test as a Means of Determining the D Zygosity of Human Red Cells (1984) (4)
The alpha-galactosyl epitope on mammalian thyroid cells. (1991) (4)
T cells interacting with the α-Gal epitope: studies in α1,3Galactosyltransferase knock-out mice (2000) (3)
Topical α-Gal Nanoparticles Enhance Wound Healing in Radiated Skin (2021) (3)
AGI-134, a fully synthetic α-Gal-based cancer immunotherapy: Synergy with an anti-PD-1 antibody and pre-clinical pharmacokinetic and toxicity profiles. (2016) (3)
COVID-19 variants as moving targets and how to stop them by glycoengineered whole-virus vaccines (2021) (3)
Differential expression of alpha-Gal epitopes on pig and mouse organs. (2000) (3)
The natural attachment of thymocytes and activated T lymphocytes to normal and malignant cells: an interspecies study. (1980) (3)
Specific attachment of T-lymphocytes from cancer patients to tumor cells. (1977) (3)
Glucocorticoid-induced lysis of various subsets of acute lymphoblastic leukemia. (1983) (2)
Regulation of the cytotoxic effect of human ‘normal killer cells’ on tumor cell lines by neuraminidase-treated T-lymphocytes (1978) (2)
Squirrel monkeys hyperacutely reject porcine musculocutaneous flaps despite a lack of naturally occurring xenoantibodies. (1998) (2)
Preventing anti-Gal response in xenograft recipients by an alpha-Gal toxin. (2001) (2)
Genes coding for anti-Gal in knock-out mice for the alpha1, 3Galactosyltransferase gene: analysis by hybridomas. (2000) (2)
Human Anti-Gal IgG binds to the same receptor and mimics the effects of C. difficile in rat colon. (1996) (2)
Excessive binding of the natural anti-alpha-galactosyl IgG to sickle red cells: enhancement of red cell destruction by a physiological process. (1985) (2)
Phase I study to evaluate toxicity and feasibility of intratumoral injection of alpha-gal glycolipids in patients with advanced melanoma. (2014) (2)
Inhalation of α-gal/sialic acid liposomes: a novel approach for inhibition of influenza virus infection? (2016) (2)
Alpha-galactosyl antibody redistributes alpha-galactosyl at the surface of pig blood and endothelial cells. (1999) (2)
Increasing Efficacy of Enveloped Whole-Virus Vaccines by In situ Immune-Complexing with the Natural Anti-Gal Antibody. (2021) (2)
Inhalation of α-Gal/Sialic Acid Liposomes for Decreasing Influenza Virus Infection (2018) (1)
Elimination of anti-Gal B cells by &agr;-Gal ricin1 (2002) (1)
Chapter 5 – Anti-Gal B Cells Are Tolerized by α-Gal Epitopes in the Absence of T Cell Help (2018) (1)
Identification of B cells with receptors for alpha-Gal epitopes (Galalpha 1-3Galbeta1-4GlcNac-R) in xenograft recipients. (2000) (1)
Chapter 10 – Cancer Immunotherapy by Anti-Gal-Mediated In Situ Conversion of Tumors Into Autologous Vaccines (2018) (1)
A simple in vitro site directed mutagenesis of concatamerized cDNA by inverse polymerase chain reaction. (1992) (1)
Anti-Gal and Anti-Non Gal Antibody Barriers in Xenotransplantation (2012) (1)
Why Do We Produce Anti-Gal (2017) (1)
Structure Function Studies of a New World Monkey (1999) (1)
Anti-Gal Interaction With Trypanosoma , Leishmania , and Plasmodium Parasites (2018) (1)
Anti-Gal Comprises Most of Anti-Blood Group B Antibodies (2018) (1)
Preformed and elicited antibodies to pig antigens in nonhuman primates and humans (2001) (1)
Acceleration of Wound and Burn Healing by Anti-Gal/α-Gal Nanoparticles Interaction (2018) (1)
Topical Alpha-Gal Nanoparticles Enhances Wound Healing in Radiated Tissue (2019) (1)
T cells interacting with the alpha-Gal epitope: studies in alpha1, 3Galactosyltransferase knock-out mice. (2000) (1)
alpha-galactosyl (Galalpha1-3Galbeta1-4GlcNAc-R) epitopes on human cells: synthesis of the epitope on human red cells by recombinant primate alpha1,3galactosyltransferase expressed in E.coli. (1995) (1)
58: ACCELERATED PORCINE WOUND HEALING AFTER TREATMENT WITH ALPHA-GAL NANOPARTICLES (2011) (1)
Anti-Gal and Autoimmunity (2018) (0)
producing the natural anti-Gal antibody One percent of human circulating B lymphocytes are capable of (2011) (0)
LONG-TERM FOLLOW-UP OF ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH AN IMMUNOCHEMICALY MODIFIED PORCINE XENOGRAFT (2009) (0)
Autologous Tumor Vaccines Targeted In Vivo by Anti-GAL to Antigen Presenting Cells: A Phase I Study in Progress (2005) (0)
Chapter 2 Why Do We Produce Anti-Gal Evolutionary Appearance of Anti-Gal in Old World Primates (2018) (0)
Abstract 135: Anti α-Gal Nanoparticles Ameliorate Radiation-Induced Wound Healing Impairment (2019) (0)
Paleo‐immunology of human anti‐carbohydrate antibodies preventing primate extinctions (2022) (0)
Aberrant activity of alpha 1 3 galactosyltransferase and autoimmunity in graves disease (1990) (0)
Chapter 9 – Anti-Gal-Mediated Amplification of Viral Vaccine Efficacy (2018) (0)
ANTI‐CD40L TRANSIENTLY SUPPRESSES PRODUCTION OF ANTI‐GAL IgG BUT NOT IgM IN &agr;1,3GALACTOSYLTRANSFERASE KNOCK‐OUT MICE IMMUNIZED WITH PIG KIDNEY MEMBRANES.: Abstract# 143 (2000) (0)
α-Gal: Antigen-Stimulated Macrophage-Directed Accelerated Wound Healing (2017) (0)
A novel approach for inhibiting progression of flu virus infection at early stages of the disease by inhalation of α-Gal/SA liposomes (2015) (0)
Xenograft-like destruction of tumors and their conversion into vaccines by intratumoral injection of {alpha}-gal glycolipids (2007) (0)
Natural Xenoreactive Antibodies (2002) (0)
Anti-Gal as Cancer Cell Destroying Antibody and as Antibiotics Targeted by α-Gal Bifunctional Molecules (2018) (0)
3.13 – Evolution and Clinical Significance of the α-Gal Epitope (2007) (0)
Anti-Gal and Other Immune Barriers in Xenotransplantation (2018) (0)
S10.5 Binding ofClostridium difficile toxin A to glycosphingolipids; identification of a novel binding-active carbohydrate sequence present in human tissue (1993) (0)
Anti-Gal and Anti-non Gal Antibodies in Regeneration of Extracellular Matrix Bio-Implants (2018) (0)
S2.15 Minimal size of active primateα1,3 galactosyltransferase (1993) (0)
Significance of the Evolutionary α1,3-Galactosyltransferase (GGTA1) Gene Inactivation in Preventing Extinction of Apes and Old World Monkeys (2014) (0)
Anti-Gal IgE Mediates Allergies to Red Meat (2018) (0)
TOLERANCE INDUCTION TO ABO BLOOD GROUP ANTIGENS BY USING AUTOLOGOUS LYMPHOCYTES ENGINEERED TO EXPRESS THE COGNATE ANTIGEN: 1485 (2008) (0)
Regeneration of Injured Spinal Cord and Peripheral Nerves by α-Gal Nanoparticles (2018) (0)
Anti- (cid:97) -Galactosyl Immunoglobulin A (IgA), IgG, and IgM in Human Secretions† (1995) (0)
on memory B cells by syngeneic lymphocytes expressing the antigen: II. Tolerance induction Tolerance induction to a mammalian blood group like carbohydrate antigen (2013) (0)
Abstract: Improving Wound Healing Using α-gal: Antibody Stimulated Macrophage Directed Wound Healing (2016) (0)
Chapter 14 – Post Infarction Regeneration of Ischemic Myocardium by Intramyocardial Injection of α-Gal Nanoparticles (2018) (0)
Structure function studies of a New World monkey alpha 1,3galactosyltransferase. Analysis of alternative splicing and expression in baculovirus system. (1999) (0)
A SIMPLE GENERAL METHOD FOR OPSONIZATION OF HUMAN AUTOLOGOUS TUMOR VACCINES BY THE NATURAL ANTI-GAL ANTIBODY (1994) (0)
Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer (2015) (0)
Abstract 2538: Immune responses to common melanoma-associated antigens following intratumoral injection of alpha-gal glycolipids in patients with advanced melanoma (2014) (0)
Proceedings: Delineation of distinct subpopulations of human thymus cells. (1975) (0)
Xenograft Like Rejection of Tumor Lesions by Gene Therapy (2005) (0)
α-Gal Nanoparticles Mediated Homing of Endogenous Stem Cells for Repair and Regeneration of External and Internal Injuries by Localized Complement Activation and Macrophage Recruitment (2022) (0)
Compositions et procedes d'obtention de vaccins comprenant des epitopes d'alpha-galactosyl (1995) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Uri Galili?

Uri Galili is affiliated with the following schools:

Uri Galili's Academic­Influence.com Rankings

Uri Galili's Degrees

Similar Degrees You Can Earn

Why Is Uri Galili Influential?

Uri Galili's Published Works

Published Works

What Schools Are Affiliated With Uri Galili?

Uri Galili's AcademicInfluence.com Rankings